Halozyme Gets FDA Orphan Drug Status for PEGPH20 to Treat Pancreatic Cancer

U.S.-based biopharmaceutical firm Halozyme Therapeutics has received orphan drug designation from the FDA for its PEGylated recombinant human hyaluronidase (PEGPH20) to treat pancreatic cancer.
Pharmaceutical Business Review